NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), Q45 Training Holdings, Inc. (NYSE: FXLV) and PROG Holdings, Inc. (NYSE: PRG). Our investigations address whether these companies have violated federal securities laws and/or engaged in other illegal business practices. For more information on each case, see the link provided.

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

On August 30, 2022, after the market close, EyePoint announced that it had received a subpoena from the United States Attorney for the District of Massachusetts. The subpoena requested documents covering the company’s sales practices for its post-surgical inflammation treatment DEXYCU.

As a result of this news, EyePoint stock fell $0.21 per share, or 2%, to close at $10.00 per share on August 31, 2022.

For more information on the EyePoint exam, visit: https://bespc.com/cases/EYPT

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

on September 22, 2022, Reuters reported that advisers to the US Food and Drug Administration “voted against recommending Spectrum Pharmaceuticals’ investigational drug to treat patients with a form of non-small cell lung cancer. The FDA panel voted 9-4 against the oral drug poziotinib, citing low efficacy, high levels of toxicity and lack of dose optimization. The panel’s decision was in line with information documents released by the drug agency on Tuesday, which raised concerns about the effectiveness of the treatment compared to existing drugs such as Daiichi Sankyo’s 4568.T AstraZenecas Enhertu.”

As a result of this news, Spectrum’s stock price fell $0.207 per share, or 32.65%, to close at $0.427 per share on September 23, 2022.

For more information on Spectrum testing, see: